Lanean...
Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
BACKGROUND: Population‐based studies previously showed an improvement in overall survival (OS) for patients with diffuse large B‐cell lymphoma (DLBCL) who received chemoimmunotherapy with rituximab. However, there is limited data (especially at the population level) that show a similar trend in OS i...
Gorde:
| Argitaratua izan da: | Cancer Med |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7402846/ https://ncbi.nlm.nih.gov/pubmed/32558356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3237 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|